F-Prime
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Tenpoint Therapeutics unlocks a £170m Series B from investors to rejuvenate vision in the aging eye
Tenpoint Therapeutics develops treatments for age-related eye conditions. Its products are designed to address presbyopia and other vision issues through clinically developed ophthalmic therapies.
T-Therapeutics secures £24m Series A extension with Tencent and BGF to develop T cell receptor therapeutics for cancer and autoimmune disease
T-Therapeutics develops next-generation T cell receptor therapies designed to target cancer and autoimmune disease, advancing bispecific molecules that selectively remove disease-driving immune cells while preserving healthy function.
Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug
Charm Therapeutics develops next generation cancer drugs designed to overcome treatment resistance, using an AI driven discovery platform to identify compounds for aggressive blood cancers such as AML.
KKR leads £300m Series C for Lighthouse to accelerate AI-driven growth in the hospitality tech market
Lighthouse provides AI-powered commercial intelligence software for hotels and hospitality groups, analysing large volumes of market and performance data to help operators optimise pricing, distribution, operations and guest experience across thousands of properties globally.
More venture news
- 20 May 2026
RemotePassRemotePass unlocks £13m Series B led by EBRD VC for cross-border payroll and workforce management platform
Series BEnterprise - 14 May 2026
IceotopeIceotope raises £19m Series B led by Two Seas Capital and Barclays Climate Ventures for liquid cooling systems for AI data infrastructure
Series BAI - 11 May 2026
Isomorphic LabsIsomorphic Labs raises £1.5bn Series B led by Thrive Capital for AI models that design new drug candidates
Series BLife Sciences
